Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Always a pleasure to team up with my partner in crime Dr. Arya Roy – a rising star in breast cancer from The Ohio State University (Go Bucks!) – to unpack some major adjuvant updates post San Antonio Breast Cancer Symposium 2025!
We cover:
MONARCHE – now showing overall survival for CDK4/6 inhibitors.
NATALEE – updated 5-year IDFS data.
LIDERA – making the biggest splash and potentially shifting us away from traditional tamoxifen/AIs toward next-generation oral SERDs.
A lot to discuss – and real implications for how we treat HR+ early breast cancer moving forward!
Watch our full conversation here.”
Title: Adjuvant Therapy Advances in HR+ Breast Cancer: Updates From NATALEE, monarchE, and lidERA
Authors: Arya Mariam Ro, Matthew Kurian
Read The Full Article
Other articles Breast Cancer on OncoDaily.